(AOF) – Pfizer jumps 5.7% to $ 53.813, the US laboratory arguably best placed to manufacture, if necessary, a new vaccine against the dreaded variant B.1.1.529 discovered in South Africa . The group and its German partner, BioNTech, have already launched a study to measure the effectiveness of their anti-covid vaccine on this new strain. The results are expected in two weeks at the latest.
In addition, the American laboratory said it was capable of developing a new vaccine in 100 days if the new variant were to prove resistant to current treatments.
“Three months may seem like a long time, but if you compare with the situation of 18 months ago, it is very reassuring in the worst case. However, it may not be fast enough to avoid new ones. restrictions this winter, “said Craig Erlam, senior market analyst, UK and EMEA at Oanda.
The AOF information reproduced on Capital.fr is taken from the AOF information service. This information is protected by intellectual property rights owned by OPTION FINANCE SAS, publisher of the AOF real-time stock market information service, and its contributors. Consequently, any reproduction, copy, duplication, modification, transfer, redistribution, translation, commercial or non-commercial exploitation, creation of hypertext link or reuse in any way whatsoever of this information is subject to the prior written consent of OPTION FINANCE SAS and its contributors. AOF can be reached at the following address [email protected] OPTION FINANCE SAS collects its data from sources it considers the most reliable. However, subject to gross negligence, OPTION FINANCES SAS and its contributors in no way guarantee the absence of errors and defects, even hidden, nor the exhaustiveness or lack of conformity for any use whatsoever of these data and of OPTION FINANCE. SAS or one of its contributors, and cannot be held responsible for delays or interruptions that could affect access to them. The user of the OPTION FINANCE SAS service will use AOF data at his own risk and must hold OPTION FINANCE SAS and its contributors harmless from any claim resulting from this use.
Receive our latest news
Every morning, the information to remember about financial markets.